French Gene & Cell Therapy Trials To Get Own Fast-Track Approval Process

Experimental gene and cell therapy products are to get a boost from the French regulator in the form of a new fast-track clinical trial approval process. This is the third accelerated pathway to be introduced as part of efforts to speed up patient access to new medicines.

Gene therapy
France is to implement a fast-track approval pathway for gene and cell therapy • Source: Shutterstock

The French regulatory agency ANSM is to introduce another fast-track clinical trial approval pathway, this time for trials of gene and cell therapy, from the beginning of 2019.

The move is part of ANSM’s drive to speed up trial approval times for, and patient access to, innovative new...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from France

More from Europe

England’s NHS Plan Eyes Cancer Vaccine Boost, Single Formulary & ‘Pay For Impact’ Drug Deal

 

The creation of a single national formulary for medicines prescribing that could impact industry is among the action points in the UK government’s new 10-year health plan for the National Health Service in England.

Denmark Sets New EU Benchmark With 14-Day Clinical Trial Review Timeline

 
• By 

Denmark is shaking up clinical trial timelines with a new process for reviewing applications for early-phase mono-national trials that is twice as fast as the standard timelines in the EU and the UK.

Industry Groups Back EU Life Sciences Strategy As Commission Pledges Clinical Trial Investment

 

Industry associations EFPIA, EUCOPE and EURORDIS have praised the European Commission’s newly launched life sciences strategy, which will see investment funnelled into improving the clinical trial ecosystem and supporting advanced therapy development.